Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

he treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... Switzerland (PRWEB) May 22, 2013 ... for industrial biotechnology, drug discovery, and life science ... Genedata Selector ™ as its bioinformatics platform ... production-relevant organisms. Genedata will provide AB Enzymes, one ... with a hosted solution of Genedata Selector accompanied ...
(Date:5/22/2013)... Earth, MN (PRWEB) May 22, 2013 ... Royal Medical Supplies Pty Ltd are pleased to ... Medical is the Australian and New Zealand distributor of ... Motorsport V8 Supercar Team participated in the Austin 400 ... has entered into an agreement that involves each car ...
(Date:5/22/2013)... 2013 The ability to sequence ... information they encode. There are now a suite ... of ribosome protected fragments) that dramatically expand our ... speakers include Dr. Jonathan Weissman, an Investigator with ... Hughes Medical Institute, who will present recent applications ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... Medical,Innovations, Inc. (Amex: IMA ), a leading ... consumer and professional markets, announced,today that it will ... and Mid,(Smid) Cap Conference being held March 26-27, ... Zwanziger, Chief Executive Officer, and Jon Russell,Vice President, ...
... Corporation today,announced that Blake M. Paterson M.D., its ... Bioscience Award from the Greater Baltimore Council.,Dr. Paterson ... by businesses, bioscience advocates, higher education,institutions and government ... Paterson has received this award from the Greater ...
... Pursuant to NASDAQ,Marketplace Rule 4350(b)(1)(B) (the "NASDAQ ... of the NASDAQ stock exchanges that receives a,going ... with the Securities and,Exchange Commission is required to ... this NASDAQ Rule, Insmed Incorporated (Nasdaq:,INSM), today announced ...
Cached Biology Technology:Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008 2Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award 2Insmed Announces Additional Information in Compliance With NASDAQ Rules 2
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
(Date:5/22/2013)... National Lung Screening Trial (NLST) investigators also conclude ... mortality with low-dose computed tomography (LDCT) versus chest ... primary paper is achievable at experienced screening centers ... more information to share with their patients about ... screening following today,s publication in the New ...
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Tests lead to doubling of fuel cell life 2
... Salk Institute for Biological Studies have identified a novel ... burn fat, a discovery that suggests new ways to ... , Genetically engineered mice, in which the pathway was ... a high-fat diet, the Salk team led by Marc ...
... household cleaners and air fresheners emit toxic pollutants at ... a new study by researchers at the University of ... levels to some of the pollutants ?and to the ... with ozone ?may exceed regulatory guidelines when a large ...
... San Diego (UCSD) School of Medicine shows that liver ... death and renewal. , The research, appearing online the ... the journal Proceedings of the National Academy of Sciences, ... proliferation. The findings by Michael Karin, Ph.D., professor ...
Cached Biology News:Chewing up a key regulator of fat synthesis keeps mice lean despite a high-fat diet 2Chewing up a key regulator of fat synthesis keeps mice lean despite a high-fat diet 3Many cleaners, air fresheners may pose health risks when used indoors 2Many cleaners, air fresheners may pose health risks when used indoors 3Many cleaners, air fresheners may pose health risks when used indoors 4Many cleaners, air fresheners may pose health risks when used indoors 5Many cleaners, air fresheners may pose health risks when used indoors 6Cycles of cell death, proliferation key to liver cancer 2